US Tech IP Strategy: How Silicon Valley IP Teams Use AI to Monitor Competitor Filings and Protect Market Position

US Tech IP Strategy: How Silicon Valley IP Teams Use AI to Monitor Competitor Filings and Protect Market Position

Introduction The top 20 US technology companies file between 2,000 and 5,000 patent applications per year. At that velocity, a competitor can file 200 patents in a new technology sub-domain in a single quarter — declaring an R&D pivot, staking...

US Biotech and Pharma Patent Strategy: How AI Manages Prior Art, Continuations, and Portfolio Lifecycle

US Biotech and Pharma Patent Strategy: How AI Manages Prior Art, Continuations, and Portfolio Lifecycle

Introduction In US biotech and pharma patent practice, the most important prior art reference is often not a patent at all. It is a paper in a peer-reviewed journal, a clinical trial registration, a conference abstract, or a regulatory submission....

Filing Patents at the USPTO in 2026: How AI Handles Prior Art, IPR Defence, and Alice Rejections

Filing Patents at the USPTO in 2026: How AI Handles Prior Art, IPR Defence, and Alice Rejections

Introduction US patent teams in 2026 are fighting on two fronts simultaneously. In prosecution, Section 101 Alice rejections continue to be the most common final rejection for software and AI patent applications — affecting more than 40% of applications in...

Race: How AI Tracks the IPC, Identifies White Space, and Guides Clean Energy IP Strategy

Europe’s Green Tech Patent Race: How AI Tracks the IPC, Identifies White Space, and Guides Clean Energy IP Strategy

Introduction The European Green Deal committed €1 trillion to clean energy transition over the decade to 2030. The patent filing activity that commitment has generated is visible in every major cleantech technology class: solar photovoltaics, offshore wind, green hydrogen, battery...

European Pharma IP: How AI Manages Prior Art, Patent Opposition, and SPC Strategy for Life Sciences Teams

European Pharma IP: How AI Manages Prior Art, Patent Opposition, and SPC Strategy for Life Sciences Teams

Introduction A European pharmaceutical patent does not expire when the 20-year term ends. Supplementary protection certificates extend patent protection for marketed drugs by up to five years — commercially critical for products that require years of regulatory approval before reaching...

Spain and Southern Europe: AI Prior Art Search for IP Teams Working Across the EPO and OEPM

Spain and Southern Europe: AI Prior Art Search for IP Teams Working Across the EPO and OEPM

Introduction Spain is one of Europe’s largest pharmaceutical markets and home to major innovators including Rovi, Almirall, and Grifols. Its automotive sector — anchored by SEAT and dozens of component manufacturers — files significant patent activity across EPO and the...

   

© 2026 XLSCOUT. All Rights Reserved.